NCT02637154

Brief Summary

This study investigates the effect of motivational interviewing and intensive education on HbA1c values and glucose variability in poorly controlled adolescent T1D patients. In the present study motivational interviewing (MI) will be integrated to clinicians' daily practice, as a part of normal clinical visit. In this randomized, controlled trial hypothesis is, that applying motivational interviewing during regular clinical visits results in better acceptance and subsequently enhanced metabolic control in adolescents with poorly controlled type 1 diabetes.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2015

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 10, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 22, 2015

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

August 3, 2018

Status Verified

August 1, 2018

Enrollment Period

2.9 years

First QC Date

December 10, 2015

Last Update Submit

August 1, 2018

Conditions

Keywords

AdolescentType 1 diabetesMetabolic controlMotivational interviewing

Outcome Measures

Primary Outcomes (2)

  • Change in HbA1C values (mmol/mol)

    HbA1c levels (mmol/mol) are measured in every visit (AfinionTM).

    12 months

  • Change in glycaemic variability

    Six days blinded continuous glucose monitoring (CGM) (iPro, Medtronic) will be performed at baseline and during the follow-up. Blinded CGM curves (0 and 12mo) will be analyzed to study effect on glycemic variability. Standard deviation (SD) of blood glucose values and mean amplitude of glycemic excursions (MAGE) will be used as parameters to define glycemic variability.

    12 months

Secondary Outcomes (11)

  • Influence of changes in markers of vascular health (IMT)

    12 months

  • Influence of changes in markers of vascular health (PWV)

    12 months

  • Influence of changes in bone mineral density (BMD)

    12 months

  • Influence of changes in quality of life

    12 months

  • Influence of changes in markers of inflammation (IL-6 - pg/ml)

    12 months

  • +6 more secondary outcomes

Study Arms (2)

Motivational Interviewing

ACTIVE COMPARATOR

With 30 patients Motivational Interviewing method will be used during each visit

Behavioral: Motivational Interviewing

Standard Education

ACTIVE COMPARATOR

With 30 patients Standard Education material will be used during each visit

Behavioral: Standard Education

Interventions

Motivational Interviewing method

Motivational Interviewing

Standard Education material will be used

Standard Education

Eligibility Criteria

Age12 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may not qualify if:

  • celiac disease with poor control; diagnosis of psychiatric disease; and other chronic disease requiring per oral glucocorticoid treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo

Espoo, 00029, Finland

Location

Helsinki University Central Hospital, Pediatric Endocrinology Unit

Helsinki, 00029, Finland

Location

Oulu University Hospital, Pediatric Endocrinology Unit

Oulu, Finland

Location

Related Publications (9)

  • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group; Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.

    PMID: 19636033BACKGROUND
  • Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003 Apr;26(4):1052-7. doi: 10.2337/diacare.26.4.1052.

    PMID: 12663572BACKGROUND
  • White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001 Dec;139(6):804-12. doi: 10.1067/mpd.2001.118887.

    PMID: 11743505BACKGROUND
  • Channon S, Smith VJ, Gregory JW. A pilot study of motivational interviewing in adolescents with diabetes. Arch Dis Child. 2003 Aug;88(8):680-3. doi: 10.1136/adc.88.8.680.

    PMID: 12876161BACKGROUND
  • Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12.

    PMID: 15826439BACKGROUND
  • Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970 Sep;19(9):644-55. doi: 10.2337/diab.19.9.644. No abstract available.

    PMID: 5469118BACKGROUND
  • Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58(6):266-72. doi: 10.1159/000066441.

    PMID: 12446989BACKGROUND
  • Sarkola T, Redington A, Keeley F, Bradley T, Jaeggi E. Transcutaneous very-high-resolution ultrasound to quantify arterial wall layers of muscular and elastic arteries: validation of a method. Atherosclerosis. 2010 Oct;212(2):516-23. doi: 10.1016/j.atherosclerosis.2010.06.043. Epub 2010 Jul 7.

    PMID: 20673898BACKGROUND
  • Pulkkinen MA, Tuomaala AK, Hero M, Gordin D, Sarkola T. Motivational Interview to improve vascular health in Adolescents with poorly controlled type 1 Diabetes (MIAD): a randomized controlled trial. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001216. doi: 10.1136/bmjdrc-2020-001216.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Interventions

Motivational Interviewing

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Directive CounselingCounselingMental Health ServicesBehavioral Disciplines and ActivitiesHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Mari Pulkkinen, MD PhD

    Specialist in Pediatric Endocrinology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

December 10, 2015

First Posted

December 22, 2015

Study Start

October 15, 2015

Primary Completion

September 1, 2018

Study Completion

December 1, 2018

Last Updated

August 3, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations